Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 15/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358350 | 0.80 | HTR2A (0.40) | RENHTR1AHTR2AHTR2BADRA1D | |
| SCHEMBL21360025 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL21358713 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL21358515 | 0.65 | CYP2B6 (0.39) | RENHTR1AHTR2AHTR2BADRA1D | |
| SCHEMBL21358516 | 0.65 | CYP2B6 (0.39) | RENHTR1AHTR2AHTR2BADRA1D | |
| SCHEMBL20482529 | 0.62 | ALDH1A1 (0.34) | — | |
| SCHEMBL21360090 | 0.62 | HTR2C (0.39) | HTR1AHTR2AHTR2BHTR2CHTR7 | |
| SCHEMBL21360092 | 0.62 | HTR2C (0.39) | HTR1AHTR2AHTR2BHTR2CHTR7 | |
| SCHEMBL21358269 | 0.60 | ALDH1A1 (0.39) | HTR1AADRA1B | |
| SCHEMBL3046387 | 0.60 | CHRNA7 (0.48) | HTR1AHTR2AHTR2BHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | REN 659/4885HTR1A 1102/4885HTR2A 1266/4885 |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HPD, CYP24A1 | REN 659/4885HTR1A 1102/4885HTR2A 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.